848 related articles for article (PubMed ID: 30026341)
21. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
22. Role of arsenic trioxide in acute promyelocytic leukemia.
Iland HJ; Seymour JF
Curr Treat Options Oncol; 2013 Jun; 14(2):170-84. PubMed ID: 23322117
[TBL] [Abstract][Full Text] [Related]
23. Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators.
Gill HS; Yim R; Kumana CR; Tse E; Kwong YL
Cancer; 2020 Jul; 126(14):3244-3254. PubMed ID: 32365228
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.
Lou Y; Tong H; Yu W; Wei J; Xu W; Mao L; Jin J
Leuk Res; 2019 Aug; 83():106168. PubMed ID: 31202077
[TBL] [Abstract][Full Text] [Related]
25. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
Breccia M; Foà R
Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcome of acute promyelocytic leukemia treated with all-
Abaza Y; Kantarjian H; Garcia-Manero G; Estey E; Borthakur G; Jabbour E; Faderl S; O'Brien S; Wierda W; Pierce S; Brandt M; McCue D; Luthra R; Patel K; Kornblau S; Kadia T; Daver N; DiNardo C; Jain N; Verstovsek S; Ferrajoli A; Andreeff M; Konopleva M; Estrov Z; Foudray M; McCue D; Cortes J; Ravandi F
Blood; 2017 Mar; 129(10):1275-1283. PubMed ID: 28003274
[TBL] [Abstract][Full Text] [Related]
27. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
Powell BL; Moser B; Stock W; Gallagher RE; Willman CL; Stone RM; Rowe JM; Coutre S; Feusner JH; Gregory J; Couban S; Appelbaum FR; Tallman MS; Larson RA
Blood; 2010 Nov; 116(19):3751-7. PubMed ID: 20705755
[TBL] [Abstract][Full Text] [Related]
28. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.
Adès L; Chevret S; Raffoux E; de Botton S; Guerci A; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Maloisel F; Deconinck E; Ferrant A; Thomas X; Fegueux N; Chomienne C; Dombret H; Degos L; Fenaux P;
J Clin Oncol; 2006 Dec; 24(36):5703-10. PubMed ID: 17116939
[TBL] [Abstract][Full Text] [Related]
29. Advances in therapies for acute promyelocytic leukemia.
Kamimura T; Miyamoto T; Harada M; Akashi K
Cancer Sci; 2011 Nov; 102(11):1929-37. PubMed ID: 21790894
[TBL] [Abstract][Full Text] [Related]
30. Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
Henzan H; Takase K; Kamimura T; Mori Y; Yoshimoto G; Iwasaki H; Nagafuji K; Ogawa R; Eto T; Uchida N; Fujisaki T; Kato K; Minami M; Kikushige Y; Akashi K; Miyamoto T;
Int J Hematol; 2020 Sep; 112(3):349-360. PubMed ID: 32524309
[TBL] [Abstract][Full Text] [Related]
31. Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).
Kutny MA; Geyer S; Laumann KM; Gregory J; Willman CL; Stock W; Larson RA; Powell BL; Feusner JH
Pediatr Blood Cancer; 2019 Mar; 66(3):e27542. PubMed ID: 30393935
[TBL] [Abstract][Full Text] [Related]
32. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F
J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939
[TBL] [Abstract][Full Text] [Related]
33. ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.
Long ZJ; Hu Y; Li XD; He Y; Xiao RZ; Fang ZG; Wang DN; Liu JJ; Yan JS; Huang RW; Lin DJ; Liu Q
PLoS One; 2014; 9(8):e104610. PubMed ID: 25122165
[TBL] [Abstract][Full Text] [Related]
34. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
Sanz MA; Montesinos P; Kim HT; Ruiz-Argüelles GJ; Undurraga MS; Uriarte MR; Martínez L; Jacomo RH; Gutiérrez-Aguirre H; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Vellenga E; Holowiecka A; González-Huerta AJ; Fernández P; De la Serna J; Brunet S; De Lisa E; González-Campos J; Ribera JM; Krsnik I; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Rego EM;
Ann Hematol; 2015 Aug; 94(8):1347-56. PubMed ID: 25975975
[TBL] [Abstract][Full Text] [Related]
35. Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.
Lengfelder E; Hanfstein B; Haferlach C; Braess J; Krug U; Spiekermann K; Haferlach T; Kreuzer KA; Serve H; Horst HA; Schnittger S; Aul C; Schultheis B; Erben P; Schneider S; Müller-Tidow C; Wörmann B; Berdel WE; Sauerland C; Heinecke A; Hehlmann R; Hofmann WK; Hiddemann W; Büchner T;
Ann Hematol; 2013 Jan; 92(1):41-52. PubMed ID: 23090499
[TBL] [Abstract][Full Text] [Related]
36. The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China.
Chen X; Hong Y; Zheng P; You X; Feng J; Huang Z; Wang Y
Cancer; 2020 Jan; 126(2):311-321. PubMed ID: 31714584
[TBL] [Abstract][Full Text] [Related]
37. PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.
Tang FF; Lu SY; Zhao XS; Qin YZ; Liu XH; Jia JS; Wang J; Gong LZ; Jiang Q; Zhao T; Shi HX; Chang YJ; Huang XJ; Jiang H
Br J Haematol; 2021 Dec; 195(5):722-730. PubMed ID: 34405393
[TBL] [Abstract][Full Text] [Related]
38. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Iland HJ; Bradstock K; Supple SG; Catalano A; Collins M; Hertzberg M; Browett P; Grigg A; Firkin F; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Blood; 2012 Aug; 120(8):1570-80; quiz 1752. PubMed ID: 22715121
[TBL] [Abstract][Full Text] [Related]
39. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
40. [Therapies for newly diagnosed acute promyelocytic leukemia].
Yokoyama Y
Rinsho Ketsueki; 2020; 61(9):1166-1173. PubMed ID: 33162512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
